Take a Look at (PALI) While It’s Still Early—Under 90 Minutes To Go

*Sponsored (Nasdaq: PALI) Has 5 Potential Breakout Catalysts Including… A Low Float Under 5Mn Shares Could Lead To Heightened Volatility Potential. PALI Has A $14 Analyst Target Suggesting Over 1,600% Potential Upside. Strong 2025 News Announcements Could Draw Serious Attention. Consider Pulling Up (PALI) Before It's Too Late…     May 27, 2025 (Nasdaq: PALI) Just Hit Our Radar! Dear Reader, In the field of gastrointestinal therapeutics, a clinical-stage biopharmaceutical innovator is making notable strides with a novel approach to treating challenging inflammatory conditions. Recent presentations at major scientific congresses have highlighted the promise of a colon-specific PDE4 inhibitor prodrug, which has demonstrated both efficacy in preclinical models and a favorable safety profile in early human studies. With its lead candidate advancing through clinical development and recognized among the top abstracts at industry conferences, this company is positioned at the forefront of efforts to address significant unmet needs in autoimmune and inflammatory bowel diseases. On top of that, this Nasdaq profile has fewer than 5Mn shares in its float, and at least one analyst providing a target suggesting triple-digit potential upside from current levels. Time could be ticking to consider this Nasdaq idea for your watchlist: Palisade Bio, Inc. (Nasdaq: PALI) Palisade Bio (Nasdaq: PALI) Is Pushing The Boundaries Of Biopharma Innovation In A Rapidly Growing Arena… Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company dedicated to developing precision therapies for immune, inflammatory, and fibrotic diseases—areas in which current treatments often prove inadequate. At the forefront of its pipeline is PALI-2108, a therapy designed for ulcerative colitis (UC), a chronic and widespread inflammatory condition. Unlike many existing options, PALI-2108 uses a gut-restricted mechanism of action, aiming to deliver targeted relief with fewer systemic side effects. A Thriving Frontier: IBD Therapies Set To Surge To $31B By 2034 The market for inflammatory bowel disease (IBD) treatments is experiencing rapid growth. Global demand is projected to exceed $22B in 2025 and reach over $31B by 2034. In the U.S. alone, spending is expected to approach $10B next year. This surge is fueled by rising cases of ulcerative colitis and Crohn's disease, highlighting the urgent need for safer and more effective therapies. Innovation is accelerating across the industry, as researchers and biotech firms pursue solutions that deliver better outcomes with fewer side effects. Advances in medical technology and precision medicine are transforming patient care, enabling more targeted approaches that could redefine how these diseases are managed. Could Machine Learning And Targeted Therapies Help Palisade Bio (Nasdaq: PALI) Outpace The Competition? Palisade Bio stands out by embracing precision medicine and machine learning in its development process. Instead of broad, systemic treatments, the company is focused on creating therapies that act specifically where needed. PALI-2108, for example, is a gut-restricted PDE4 inhibitor, designed to minimize unwanted exposure elsewhere in the body and reduce side effects while maximizing effectiveness. The company is also leveraging machine learning to refine patient selection. By analyzing biomarkers, Palisade Bio aims to identify individuals most likely to benefit from its therapies, increasing the chances of success and personalizing treatment. With a strategy rooted in targeted, personalized medicine, Palisade Bio is positioned to make a significant impact in the rapidly expanding IBD treatment landscape. As the need for innovative solutions grows, the company's focus on precision and patient-specific therapies could help set new standards in care for those affected by chronic inflammatory diseases. Grab Sources And More Here: PALI Presentation. PALI Website. Here's 5 Key Reasons Why Palisade Bio (Nasdaq: PALI) Tops Our Watchlist This Week... #1. PALI has a fairly low float (volatility potential on watch). Yahoo Finance is reporting PALI to have a float of approximately 4.46M shares. That means volatility potential could be through the roof on a daily basis due to so few shares being available. #2. PALI has a strong analyst target suggesting significant upside potential. At $14.00, PALI has at least one impressive analyst target. According to the research universe of Ladenburg Thalmann Co. Inc., they believe PALI has the potential to reach $14. From Friday's close, that target suggests PALI may have a potential upside over 1,600%! Could PALI be severely undervalued from current levels? #3. PALI has pushed above 4 key technical chart levels recently. According to PALI's chart, support could be growing at 4 key levels. In the last week, PALI has pushed through these 4 technical chart levels: 20-Day Simple Moving Average (SMA) 50-Day SMA 5-Day Exponential Moving Average (EMA) 13-Day EMA With resistance having potentially broken down at these 4 technical levels, is strong support now taking its place? #4. Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases. Palisade Bio unveiled promising preclinical results for PALI-2108, a colon-specific PDE4 inhibitor, showing significant improvement in colitis symptoms and inflammation in mouse models. The drug demonstrated strong efficacy, safety, and minimal central nervous system toxicity, supporting its potential for treating ulcerative colitis and other inflammatory bowel diseases. #5. Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108. Palisade Bio completed dosing in its Phase 1a clinical trial of PALI-2108, evaluating safety and tolerability in healthy volunteers. The trial is progressing as planned, with topline data expected by the end of May 2025, supporting continued development for ulcerative colitis treatment. We have both eyes tracking (Nasdaq: PALI) right now. Be on the lookout for more info soon. Take a look at (PALI) while it's still early. Sincerely,  Jeff Ackerman Managing Editor Stock News Trends   StockNewsTrends.com ("StockNewsTrends" or "SNT" ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 05/26/2025 and ending on 05/27/2025 to publicly disseminate information about (PALI:US) via digital communications. Under this agreement, TD Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, TD Media LLC has been paid fifty seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (PALI:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/pali-mX9pa/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe {recipient's email} Update Profile | Constant Contact Data Notice Sent by jeff@stocknewstrends.com powered by Try email marketing for free today!